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ABBREVIATIONS 
 
AMPK: Adenosine monophosphate-activated protein kinase 
Atg: Autophagy-related gene 
AV: Autophagic vacuoles 
BiP: Binding immunoglobulin protein 
CMA: Chaperone-mediated autophagy 
DC: Diabetic cardiomyopathy 
DDR: DNA damage repair 
ER: Endoplasmic reticulum 
ERAD: endoplasmic reticulum-associated degradation 
GRP-78: Glucose-regulated protein 
GSK3: Glycogen synthase kinase-3 
IR: Ischemia-reperfusion 
JNK1: Jun NH2-terminal kinase 1 
LAMP-2: Lysosome-associated membrane protein-2 
miRNA: microRNAs 
mTOR: mammalian target of rapamycin 
NAC: N-acetyl cysteine 
OA: Osteoarthritis 
ROS: Reactive oxygen species 
SIPS: Stress-induced premature senescence 
T2DM: Type 2 diabetes mellitus 
ULK1: Uncoordinated 51-like kinase 1 
UPR: Unfolded protein response 
VF: Ventricular fibrillation 
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ABSTRACT 
 
Oxidative stress placed on tissues involved in pathogenesis of a disease, activates 
compensatory metabolic changes, such as DNA damage repair that in turn, cause intracellular 
accumulation of detritus and “proteotoxic stress”, leading to emergence of “senescent” 
cellular phenotypes, which express high levels of inflammatory mediators, resulting in 
degradation of tissue function. Proteotoxic stress resulting from hyperactive inflammation 
following reperfusion of ischemic tissue, causes accumulation of proteinaceous debris in cells 
of the heart in ways that cause potentially fatal arrhythmias, in particular, ventricular 
fibrillation (VF). An adaptive response to VF is occurrence of autophagy, an intracellular bulk 
degradation of damaged macromolecules and organelles that may restore cellular and tissue 
homeostasis, improving chances for recovery. Nevertheless, depending on the type and 
intensity of stressors and inflammatory responses, autophagy may become pathological, 
resulting in excessive cell death. The present review examines the multilayered defenses cells 
have evolved to reduce proteotoxic stress by degradation of potentially toxic material 
beginning with endoplasmic reticulum-associated degradation; and the unfolded protein 
response, which are mechanisms for removal from the ER of misfolded proteins; then 
progressing through the stages of autophagy, including descriptions of autophagosomes and 
related vesicular structures which process material for degradation and autophagy-associated 
proteins including Beclin-1 and regulatory complexes. The physiologic roles of each mode of 
proteotoxic defense will be examined along with consideration of how emerging 
understanding of autophagy, along with a newly discovered regulatory cell type called 
telocytes, may be used to augment existing strategies for prevention and management of 
cardiovascular disease. 
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I. Ischemia-reperfusion injury and ventricular fibrillation. 
 
Ia - Inflammatory tissue damage, disease and trauma. 
The major symptoms of all diseases known at the time of this writing are due at some level, to 
inflammatory adaptive processes leading to autoreactive tissue damage. Typically, microbial 
or toxic challenge, physical injury, or disruption of normal physiology by genetic defect or 
neoplasm, triggers defensive responses that have evolved to counteract primary threats, but 
that may remain activated at high levels, causing prolonged and deleterious pro-inflammatory 
signaling. Failure of regulatory mechanisms to restore these processes to normal activity 
levels, results in chronic inflammation, characterized by sustained production of highly 
reactive oxygen-containing compounds called reactive oxygen species (ROS), that subject 
tissue to oxidative stress – often for the lifetime of an individual. Disruption of control over 
inflammation in cardiovascular tissue, disrupts coordinated contractility of heart muscle, 
resulting in ventricular fibrillation and other arrhythmic disorders [1,2]. A primary trigger for 
onset of chronic inflammatory syndromes, is ischemia, a condition in which functional 
impairment and loss of structural integrity of affected tissue occurs as a consequence of 
oxygen and nutrient deprivation [3]. These processes cause increased generation of reactive 
oxygen-containing molecules by cardiovascular and immune cells, which promote tissue 
damage and impair cardiac function [1,4]. Interestingly, subjecting the heart to very brief, 
periods of ischemia, protects the myocardium from subsequent ischemic insult. A major 
mechanism contributing to this effect has been shown to involve ROS-mediated induction of 
antioxidant enzymes, prominently superoxide dismutase, which remain elevated and/or 
increase in responsiveness, with resulting increases in the efficiency with which ROS are 
scavenged [5,6]. Recent work by our laboratory, has demonstrated that naturally occurring 
inducers of another major antioxidant defense enzyme, heme oxygenase-1, also exhibits 
powerful cardioprotective effects [7,8]. 
 
Ib - Ischemia-mediated disruption of cellular and tissue homeostasis. 
Ischemic effects are associated with conditions of disease or trauma affecting circulation and 
may also occur following surgery in which blood supply to a tissue or organ is intentionally 
restricted. A resulting hyperactivation of oxidative metabolism occurs as a result of 
intracellular accumulation of highly reactive oxygen-containing compounds (reactive oxygen 
species – ROS) along with increased activity by proteolytic enzymes. These outcomes of 
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cellular damage, typically interfere with normal homeostatic signaling processes (in particular 
those involving calcium), disrupting mitochondrial activity and causing loss of cell 
compartmentalization and membrane integrity [9], which in heart tissue, may manifest as 
arrhythmias [1,2]. 
Ic – Ischemia-reperfusion (IR) injury and arrhythmias. 
Restoration of blood flow to ischemic tissue results in high levels of  ROS activity and 
resulting oxidative stress, following restoration of circulation, an effect called ischemia-
reperfusion (IR) injury [9,10]. Such reoxygenation by blood reperfusing ischemic tissue, 
restores some aspects of healthy homeostasis, however, rapid increases in ROS levels also 
trigger abnormally intense inflammation, leading to debilitation and occasionally death when 
a vital organ is affected [3]. Cells of the cardiovascular, kidney and nervous systems are 
particularly susceptible to IR injury due the stringent requirement of these cells on normal 
cellular redox balance [11,12]. 
A hallmark of IR injury to the heart and a major cause of death in human cardiovascular 
disease, is fibrillation, an arrhythmic condition which develops from severe disruption of 
cardiac rhythm triggered by chemical and physical damage to cells of the heart [13]. A 
commonly occurring and often fatal form of this syndrome, which affects ventricular 
myocardium, is ventricular fibrillation (VF) [1,14]. IR-induced VF occurs suddenly after the 
onset of reflow, and has been observed in all animal species [15]. In humans, this syndrome 
occurs during thrombolytic therapy and cardiac surgery [16,17]. IR-induced injury to the 
myocardium, often is observed with cardiovascular pathologies, including heart failure 
coronary artery lesions and arrhythmias, causing cell death through the major mechanisms 
including necrosis, apoptosis, and autophagy, which can be together termed as 
“necroapoptophagy” [18]. 
II. Consequences of IR injury and physiological countermeasures. 
IIa - Proteotoxic stress, cellular senesence and adaptive countermeasures. 
The major symptoms of cardiovascular disease, including VF, which are often initiated by IR-
associated oxidative damage, also may be exacerbated by hypertrophic cell growth resulting 
from greatly elevated activation of a serine/threonine kinase responsible for synthesis of cell 
components called mammalian target of rapamycin (mTOR) [19]. Damaged cells with high 
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mTOR activity, often lose their proliferative potential, proper control over proteostasis and 
accumulate aggregates of protein precursors, which disrupt normal cellular metabolism leads 
to a phenomenon known as proteotoxic stress [20]. Proteotoxic stress-induced cell 
enlargement not counterbalanced by proliferation, causes emergence of senescent cellular 
phenotypes, in which buildup of incorrectly folded polypeptide aggregates, disrupt 
compartmentalization of cell components, stimulating elevated expression of inflammatory of 
cytokines [18]. As an organism ages, each component tissue accumulates steadily increasing 
numbers of senescent cells, which cause tissue environments to become progressively more 
proinflammatory [21]. Age-associated increase in senescent cell numbers is augmented by 
stress placed on tissues as a result of trauma or disease, resulting in oxidative damage-induced 
conversion of cells to senescent phenotypes – a process known as stress-induced premature 
senescence (SIPS) [21]. Progressively pro-inflammatory tissue environments resulting from 
buildup of senescent cells, promotes tumor growth, along with progressive tissue and organ 
damage [21].  The extreme sensitivity of cardiovascular cells to proteotoxic stress, provides a 
mechanistic explanation for heart disease as the most frequent cause of death from “natural 
causes” [12]. This phenomenon is particularly evident in diseases for which age-associated 
physical decline is greatly accelerated – notably Hutchinson-Gilford progeria syndrome 
(HGPS). HGPS-afflicted individuals express a defective variant of the nuclear lamin A 
protein, which rapidly forms toxic aggregates triggering accelerated accumulation of 
senescent cellular forms in all tissue, promoting inflammatory tissue damage – which is 
reflected as accelerated physical aging. HGPS humans typically die at about age 13 from heart 
failure [22]. The primary focus of the present review is an examination of "housecleaning" 
mechanisms of autophagy, by which cells respond to a major consequence of oxidative 
damage to cell macromolecules, which is intracellular accumulation of toxic detritus in cells 
of the heart and other tissue – defined above as proteotoxic stress. Autophagy has recently 
been recognized as a vitally important cytoprotective process in function of cardiovascular 
[23] and other tissue [24]. The observed protective effects of autophagy, is subject to a 
significant caveat, that autophagic activity may significantly contribute to impaired cellular  
function [25]. Thus, clinical use of strategies that modulate the autophagic response will 
probably need to be deferred until improved insight is gained into potentially adverse effects 
of autophagy when applied in prevention or treatment of disease. This limitation 
notwithstanding, processes whereby enhancement of autophagy may ameliorate 
arrythmogenesis by attenuating the effects of proteotoxic stress, provide a paradigm for 
therapeutic modulation of autophagy in prevention and management of VF and other 
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arrhythmias. In particular, drug interventions that suppress intracellular accumulation of toxic 
protein aggregates by suppressing activity of mammalian target of rapamycin (mTOR) and 
increasing adenosine monophosphate-activated protein kinase (AMPK) exhibit particular 
promise –and may have corollary benefit in life extension research, due to inhibition of 
geroconversion to pro-inflammatory senescent cell phenotypes, as previously described by the 
authors [18]. 
 
IIb - Autophagy: a major cellular countermeasure to proteotoxic stress. 
Hypertrophy and senescence of cardiac cells leading to VF and related pathologies may be 
significantly suppressed by inhibition of mTOR with the drug, rapamycin [26]. This effect 
occurs as a consequence of the normal cellular role of mTOR, which includes constitutive 
repression of autophagy, best defend as a “housekeeping” mechanism by which a cell clears a 
wide range of debris, including toxic protein aggregates that promote emergence of senescent 
pro-inflammatory cell types. Thus, pharmacological suppression of mTOR, which acts as a 
negative regulator of autophagy, allows enhanced autophagic clearance of toxic debris 
produced by high mTOR activity and amelioration of several major pathologies including 
cardiovascular and neurodegenerative syndromes [18,27,28]. Autophagy, thus appears to have 
evolved as an endogenous protective countermeasure to proteotoxic stressors and acts 
primarily to reduce the rate at which hyperinflammatory senescent cellular phenotypes 
accumulate in tissue [18,27]. These observations notwithstanding, autophagy may exacerbate 
pathological processes as well as inhibiting disease severity [28,29]. For this reason, it is 
essential that future strategies for prevention and management of disease that manipulate 
autophagic processes, be undertaken with an understanding of adverse side effects that may 
occur as a result of this approach. Since the present review is expected to serve as a guide by 
which improved approaches to use of autophagy in prevention and remediation of serious 
chronic illness, a short but comprehensive description of the molecular mechanisms of 
autophagy will be considered in the following sections. 
 
III. Major modes of autophagy 
IIIa - Autophagic pathways. 
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Cells are known to undergo 3 modes of autophagic activity. Peptides, minor proteins and 
other small molecules recognized by the cell as potentially toxic are removed by 
microautophagy, which involves direct uptake by the lysosomes of the targeted material for 
recycling (Figure 1) [11]. Larger categories of detritus are subject to degradation and 
recycling via macroautophagy, in which damaged or unusable proteins and cellular organelles 
become enclosed by double-walled membrane vesicles called autophagosomes, and then 
fused with lysosomes for degradation and recycling [30]. This process, mediated mainly by 
ubiquitin and enzyme-containing complexes called ULK and Beclin1–PI3KC3, is the form of 
autophagy most frequently utilized by cells for clearance of detritus in a size range capable of 
severely disrupting cellular homeostasis [31-33] – and constitutes the form of autophagy most 
frequently described as a major cellular countermeasure to accumulation of toxic protein 
aggregates [34,35]. The presence of Beclin-1 protein (autophagy-related gene: Atg 6) may be 
used as a reliable biomarker for the occurrence of autophagy in biological samples, including 
myocardial tissue [36]. A third form of the autophagic response is called chaperone-mediated 
autophagy (CMA), which is a highly selective quality control program that degrades nascent 
polypeptides if they become incorrectly folded [37]. During the process, the KFERQ region of 
the misfolded protein is recognized by chaperons and taken up by the lysosomes via channels 
formed by LAMP-2 proteins [38]. The foregoing descriptions illustrate the role of autophagy 
in cardiac and other tissue as an adaptive mechanism for maintaining healthy cellular 
homeostasis by clearing toxic cellular debris and allowing cells that might otherwise die to 
survive. Autophagic activity resulting in cell survival appears to be a significant factor in the 
amount of tissue that may survive for prolonged periods in chronically ischemic myocardium 
[39,40]. Moreover, this protective effect may be abolished with autophagy-inhibiting drugs 
such as wortmannin [41-43]. These observations notwithstanding, autophagic activity is not 
always beneficial. Under conditions of extreme tissue stress, high levels of autophagy may 
initiate cascades of pathological reactions in myocardial cells and, ultimately, deterioration of 
myocardial function [44]. 
 
IV. Autophagic response hierarchy: Cellular housecleaning mechanisms 
 
IVa - Post-translational quality control and the unfolded protein response (UPR), first-line 
countermeasures to toxic detritus.  Autophagy and related quality control mechanisms 
associated with the endoplasmic reticulum (ER), along with a protein integrity editing process 
 10 
called the unfolded protein response (UPR), represent a multilayered array of adaptive 
activities evolved by cells to mitigate debris-mediated interference with normal cellular 
function. A cell’s first line defense against accumulation of potentially harmful debris is a 
highly selective quality control program within the ER that degrades improperly folded 
nascent polypeptides during translation [45]. These mechanisms are activated at the earliest 
stages of post-translational modification and are relevant to present discussion based on their 
capacity to promote autophagic activity through triggering of the UPR, a process in which 
improperly folded proteins that evade immediate posttranslational deletion, cause alterations 
in gene expression that amplify early clearance of malfolded proteins in the ER and may also 
drive the cell into apoptosis [46]. The relationship between UPR activity and autophagy will 
be discussed further in the next section of the present review. Nascent chains which fail to 
fold properly despite enzymatic correction become complexed with a 78 kDa chaperone 
molecule called binding immunoglobulin protein (BiP) also known as glucose-regulated 
protein (GRP-78). Malfolded chains may form aggregates or complex with BiP, to enter a 
process called endoplasmic reticulum-associated degradation (ERAD). The process of ERAD 
quality control involves deposition of malfolded proteins in the cytosol through transient 
complexes formed with BiP and other chaperone molecules, followed by binding to ubiquitin 
and degradation via the ubiquitin-proteasome pathway [47]. A simplified representation of 
ERAD and related processes is shown in Figure 2. If the burden of misfolded or damaged 
proteins and toxic complexes formed by these molecules exceeds the processing capacity of 
ERAD and ubiquitin-proteasome-mediated degradation, ER stress due to their presence may 
be alleviated by a cellular adaptive response that augments ER coping mechanisms and may 
also induce cell cycle arrest or apoptotic deletion, thus eliminating the hazard posed by the 
cell should its damaged phenotype render it carcinogenic or senescent. These processes, 
collectively known as the unfolded protein response (UPR), alter gene expression and cellular 
metabolism in ways that promote and merge into autophagic degradation of a wide range of 
cellular detritus [48]. UPR activity is represented by 3 major processes, each defined by 
outcomes of dissociation and subsequent activation of each of the aforementioned BiP/GRP78 
ligands. Figure 2 is a schematic representation of the 3 signaling processes constituting arms 
of the UPR and major physiological outcomes resulting from activation of each pathway. 
IVb - Initiation and preliminary phases of autophagy. 
Challenges posed to cellular homeostasis by detritus for which ERAD and UPR responses are 
insufficiently robust, may trigger macroautophagy [31]. The first phase of this process, known 
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as autophagic sequestration, involves envelopment of cytoplasmic contents by strongly 
osmophilic ER-derived cisternae (vesicles), with membranes biochemically distinct from 
those of the ER and electron-dense, thus allowing these structures to be easily distinguished 
by electron microscopy [49]. Appearance of these primary autophagic vacuoles (AV), called 
autophagosomes represent the earliest phase in the evolution of autophagy-related cellular 
structures identifiable by microscopic analysis of cellular morphology [49]. Autophagosomes 
fuse with endosomes to form intermediary AV termed amphisomes, which typically contain 
cytoplasmic material designated for recycling, but retain significant quantities of mostly non-
denatured proteinaceous aggregates in an acidic environment, along with low concentrations 
of lysosomal enzymes [50]. Progression of autophagy continues with enlargement of 
amphisomes by fusion with autophagosomes, lysosomes and endosomes [50,51]. Eventually 
multiple fusions with lysosomes elevate the levels of lysosomal enzymes to facilitate 
significant degradation of amphisomal contents [52]. The aforementioned preliminary stages 
of the autophagic process occur in tandem with recruitment of the components, which interact 
to drive degradation of autophagosome contents. These molecules are trafficked to AV 
membranes beginning in the earliest stages of autophagosome formation and become 
progressively more coordinated as autophagy proceeds [31]. 
IVc - Major regulatory and structural components of autophagy. 
The core machinery of autophagic processes is dependent on 36 Atg proteins, which are 
highly conserved in evolution [53]. Interaction of these components following their assembly 
into the autophagosomal membranes is tightly regulated by the nutrient-sensing enzymes 
mTOR, AMPK and glycogen synthase kinase-3 (GSK3), the activities of which are 
modulated by the availability of amino acids, glucose and serum (with component growth 
factors), respectively. As shown in Figure 3, activities of each of these  aforementioned 
factors  promotes, or represses autophagy through their effect on uncoordinated 51-like kinase 
1 (ULK1), which is a serine/threonine kinase complexed with 3 major regulatory factors (Atg 
101, Atg 13 and FIP200) [31]. The ULK1 complex serves as a major central regulatory 
element in commitment to undergo autophagy and determination as to whether the outcome 
will be death or survival of the cell [31]. 
IVd – Autophagy, mTOR and cellular senescence. 
Figure 3 shows the functional relationships between the major cellular regulators of 
autophagy. As described above in section IIa, mTOR is a serine/threonine kinase which, 
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together with its associated regulatory element, raptor, responds to nutrient availability by cell 
growth-related synthesis of protein precursors to protein – which unless counterbalanced with 
proliferation, results in emergence of swollen and distorted “senescent” phenotypes which 
express high levels of inflammatory mediators contributing to impairment of tissue and organ 
function [21]. mTOR also acts on ULK1 to repress autophagy [31]. The activity of this 
enzyme is vital for a wide range of activities contributing to healthy homeostasis by cells, 
tissues and whole organisms [54], nevertheless mTOR activity becomes pathological in cells 
that sustain damage sufficient to activate the p16/p21 tumor suppressor system and causing 
cell cycle arrest, thus preventing their evolution into cancers, but fails to result in apoptotic or 
necrotic cell death [18]. Cellular senescence, may be triggered by damage to the cell as a 
result of disease or trauma – and may also be caused as a result of oxidative stress occurring 
due to deteriorated genomic organization at the end of an individual cell line`s replicative 
lifespan [18]. As described previously in section IIa, senescent cell accumulation constitutes a 
key contributor to age-related physical deterioration [18], moreover, deleting these cells as 
they emerge into senescent phenotypes has been demonstrated to maintain youthful vigor in a 
transgenic mouse model [55]. Since nutrient-driven mTOR activity is a potent negative 
regulator of autophagy, inhibition of the enzyme with drugs such as rapamycin allows 
upregulation of autophagic processes, resulting in clearance of toxic detritus, which in some 
cases may restore healthy cellular and tissue function [18]. Under physiologic conditions, 
mTOR is a component of one of two complexes, each configured for separate functions in 
maintenance of cellular metabolism. These are: mTORC1, which includes mTOR and the 
regulatory proteins Raptor: mLST8 (GL), Pras40, Deptor and Tti1/Tel2. This form regulates 
mTOR activity based on nutrient energy content and redox status [56]. The activity of mTOR 
in a second regulatory complex, mTORC2, which contains mTOR, along with rapamycin-
insensitive companion of mTOR (RICTOR), mammalian stress-activated protein kinase 
interacting protein 1 (mSIN1); and the protein GβL, is also modulated by nutrient availability 
and composition. The role of mTORC2 in cellular physiology is primarily to mediate changes 
in cytoskeletal architecture in response to cues from the cellular environment [57]. 
IVe - Role of ULK1 and Beclin1–PI3KC3 and related proteins in regulation of autophagy. 
Initiation of autophagy and its progression to either cell death or survival is dependent on 
feedback interactions between the major nutrient status sensors and ULK as shown in Figure 
3. In addition to ULK1, mTOR and GSK3, another complex of autophagy-associated proteins 
that plays a critical role in coordinating autophagic activity is Beclin-1–class III 
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phosphatidylinositol 3-kinase (PI3KC3) and Atg 14L (also known as Barkor) an associated 
trafficking and catalytic factor [58]. Beclin-1 – PI3KC3 responds to interaction between a 
variety of upstream regulators of autophagy to produce PI3P, which is a lipid mediator 
responsible for a signal cascade that maintains coordinated progression of autophagy [59]. 
Beclin-1 thus acts to relay external signals to the cell which trigger autophagy and influence 
its outcome [59]. 
IVf - Major macromolecular events in autophagic process. 
The progression of coordinated interaction between the major protein and vesicular 
components of autophagy is illustrated briefly in Figure 1. Typically, autophagy may be 
triggered by presence of toxic intracellular debris and augmented by a cell’s response to 
nutrient and redox status of its environment [18]. The availability to a cell of high nutrient 
levels, stimulates the mTOR-raptor complex to downregulate autophagy by direct 
phosphorylation of the ULK1 enzyme, along with phosphorylation of its associated regulatory 
element Atg-13 [60]. Additionally, the ability of AMPK to promote autophagy in response to 
decreased nutrient levels or feedback signaling from ULK1, is inhibited by mTORC1-
mediated phosphorylation on Ser757 [61], low nutrient-mediated decrease mTORC1 activity 
augments autophagy through de-repression of pro-autophagic signaling [31]. As shown in 
Figure 1, signaling through ULK1 and Beclin-1 –PI3KC3 catalyzes assembly of Atg proteins 
into membranes of autophagosomes, initiating the structural progression characteristic of the 
process. The lipid mediator PI3P produced by Beclin1–PI3KC3, mediates assembly of WIPI 
proteins, which are structural regulators that facilitate organization of ubiquitin-like 
conjugation systems. These systems include the Atg12–5–16 complex; and a form of Atg8 
(LC3), which undergoes covalent modification by lipidation and subsequently associates with 
autophagosomes in ways that stabilize the autophagic process. This enhancement  results in 
coordinated expansion and fusion of autophagosomal membranes [62]. 
V. Disruption in autophagic functions: role in disrupted cellular homeostasis and 
cardiovascular disease. 
Va – Contribution of autophagy and apoptosis to cardiac stress responses. 
Rapidly emerging insights into mechanisms of autophagy have revealed features of the 
process, which offer potential to develop enormously valuable approaches for prevention and 
management of a diverse range of serious chronic diseases currently refractory to medical 
intervention. Clinical use of autophagy must nevertheless be undertaken with careful 
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consideration of its damaging capacity for some of the same reasons that induction of 
apoptosis as part of a therapeutic regimen must be approached with caution. Both apoptosis 
and autophagy are adaptive mechanisms that have evolved to eliminate damaged cells and 
cellular material that may pose threats to the health of an organism. Both processes contribute 
substantially to survival of an individual when occurring at levels sufficient to meet major 
proximal threats, but become pathological when depletion of functional cells impairs healthy 
tissue homeostasis [63]. Indeed, studies of in vivo responses to hemodynamic stress reported 
in 2007, demonstrated an inverse relationship between levels of apoptosis and autophagy in 
hearts of mice responding to cardiac pressure overload [64]. Moreover, this balance between 
the two processes appeared to contribute to the adaptive capacity of hearts of animals 
subjected to the induced stressors [64]. 
 
Vb - Impairment of autophagy degrades cardiomyocyte and heart function. 
In the aforementioned studies, investigators evaluated contribution of autophagy to induced 
cardiac overpressure through use of a strain of mice bearing a transgene for Atg5 (autophagy-
related 5) protein, genetically configured to undergo cardiac-specific deletion under temporal 
control in adult mice. Since Atg5 is an essential component of autophagy, autophagy in mice 
bearing this element was abrogated. Adult mice deficient in Atg5 develop hypertrophic hearts 
with insufficient contractile activity and ventricular dilatation [64]. Deficiency in Atg7, 
another protein that autophagy cannot occur without, has also been observed to disrupt 
essential homeostatic processes when experimentally induced in mice [65]. Ultrastructural 
examination of heart tissue from Atg5-deficient mice revealed cellular changes contributing to 
malfunction of the organs, including misalignment and aggregation of mitochondria, along 
with deposition of ubiquitinated proteins and disorganized sarcomere structure [64]. 
Interestingly, these degenerative effects were present concurrent with inactivation of 
autophagy in hearts of adult mice via the inducible Atg-transgene, but were delayed by a 
week following pressure overload when the process was interrupted early in cardiogenesis 
[64]. These outcomes, suggest that constitutively occurring autophagy is a major mechanism 
by which size and functional integrity of both cardiomyocytes and whole hearts are 
maintained within normal parameters [64,66,67]. 
Vc - Autophagy-related pathophysiology of cardiovascular disease (2 major pathological 
processes). 
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The major result of disregulations in autophagy that may cause disease, are broadly grouped 
into two major outcomes of impaired autophagic activity. One disease-associated outcome is 
failure of autophagosomes to properly mature into endosomal vesicles capable of isolating 
intracellular detritus. A second class of defect occurs as a consequence of the inability of 
autolysosomes to effectively degrade the autolysosome contents [68]. Cardiac malfunctions 
arising as a result of each of these two defects are briefly considered below. 
Vd - Pathological consequence of autophagic endosomal maturation failure (LAMP2 
deficiency). 
An example of the first of the 2 aforementioned categories of autophagy deficiency-linked 
cardiovascular disease, is observed in mice deficient in lysosome-associated membrane 
protein-2 (LAMP-2), an extensively glycosylated protein present at high density in lysosomal 
membranes, which has been demonstrated as essential for normal maturation of autophagic 
vesicles, in particular, proper fusion between early and late endosomes [69]. Characterization 
of the role of LAMP-2 in constitutive autophagy, demonstrated that mice expressing a 
functionally defective variant of this protein exhibited higher mortality relative to wild type 
mice. Ultrastructural analysis of cardiovascular and other tissues of LAMP-2-deficient mice 
demonstrated extensive accumulation of early autophagic endosomes, along with persistence 
of long-lived proteins, which are normally degraded in cells with fully functional autophagic 
capacity [69]. Moreover, cardiac myocytes from LAMP-2-deficient animals were eccentric in 
structure and contractility of hearts from these animals was significantly impaired [69]. 
Interestingly, humans bearing a deficient gene for LAMP-2 develop a syndrome called 
Danon’s disease, characterized by disrupted cardiovascular function and skeletal muscle 
weakness, with numerous features in common with the aforementioned experimentally-
induced murine variant [70,71]. The parallel emergence of cardiovascular deficiencies in 
LAMP-2-deficient mice and humans, and as a consequence of disabled autophagy, 
underscores the critical nature of this process to understanding the molecular basis for heart 
disease and related conditions. 
Ve - Pathological consequence of autophagic debris degradation failure (Vici syndrome). 
A representative example of failure to fully degrade autolysosome contents is Vici syndrome, 
a multisystem recessive disorder in humans occurring due to a defect in the gene EPG5 
coding for ectopic P-granules autophagy protein 5, which regulates the ability of late 
autophagosomic vesicles to degrade their contents [68]. Persons afflicted with Vici syndrome 
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experience a cluster of adverse effects, including impaired neurological development 
immunodeficiency, eye and skin disorders, along with cardiomyopathy [68]. Electron and 
other microscopic examination of both skeletal and cardiac muscle from persons afflicted 
with this disorder reveal major cellular myopathic characteristics such as increased numbers 
of internal nuclei, abnormal glycogen deposits, fiber-depleted myofibrils, basal lamina 
redundancy with evidenced of exocytosed material between laminar layers; along with 
morphologically abnormal and maldistributed mitochondria [68]. Interestingly, analysis of 
post mortem microscopic cardiac changes in Vici syndrome patients revealed that the 
aforementioned histopathological changes were of substantially greater magnitude in left, 
versus right ventricle samples [72]. This observation underscores the importance of autophagy 
as a major contributor to cardiovascular health. The left ventricle has evolved to sustain a 
significantly higher work load than the right and its component cells are therefore subjected to 
a higher flux of reactive oxygen species than are tissue of the right ventricle. These in turn 
likely results in greater accumulation of toxic debris in left ventricular tissue and a greater 
need for constitutive clearance of this debris in order to maintain healthy cardiac function. 
The very high sensitivity of cardiac tissue to presence of toxic debris [22] makes efficient 
autophagy essential for the function of left ventricular tissue in particular - and it is therefore 
unsurprising that Vici syndrome patients exhibited a greater degree of ultrastructural 
pathogenic changes in the left, versus right ventricle. 
VI. Autophagy, diabetic cardiomyopathy and “biotherapeutic” treatment strategies. 
VIa - Diabetic cardiomyopathy. 
Diabetic cardiomyopathy (DC) is a major co-morbidity of type 2 diabetes mellitus (T2DM), 
prominently featuring progressive cardiomyocyte loss and accumulation of fibrotic tissue 
leading to disrupted ventricular function independent of any cardiovascular disease or related 
condition such as hypertension [73,74]. DC contributes substantially to death and 
incapacitation among T2DM patients [75], however, at the time of this writing, the 
pathomechanisms of this disorder have not been characterized in sufficient detail to enable 
development of effective clinical countermeasures. Insight into DC pathogenesis has recently 
been provided by studies demonstrating that AMPK activation inhibits DC through 
restoration of autophagy in cardiac cells, with the concomitant effect of reducing apoptotic 
depletion of heart tissue [76]. These observations, which suggest an inverse relationship 
between apoptosis and autophagy in diabetic hearts, may be regulated by some of the same 
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underlying molecular interactions that govern occurrence of these two processes in hearts 
responding to cardiac pressure overload [64]. Further investigation of the phenomenon of 
AMPK-mediated restoration of autophagy as a countermeasure to DC using a H9c2 cardiac 
myoblast cell model, revealed that elevated glucose decreased AMPK activity, inhibiting Jun 
NH2-terminal kinase 1 (JNK1)–B-cell lymphoma 2 (Bcl-2) signaling, allowing formation of 
Bcl-2–Beclin1 complexes resulting in inhibition of autophagy, whereas low glucose activated 
AMPK with the anti-diabetic drug metformin, promoted JNK1–Bcl-2 signaling, disrupting 
Beclin-1–Bcl-2 complexes, allowing restoration cardiac autophagy [76]. Similarly, reduced 
autophagic responses were observed in Type I diabetic mice, however, overexpression of 
Beclin-1 worsened the diabetes-induced cardiac injury [77]. In a recent study, Kanamori et. al. 
has compared the autophagic processes in hearts of Type I and Type II diabetic animals [74], 
using streptozotocin to induce Type I DM and db/db mice as Type II model. In contrast with 
the two aforementioned studies, the authors have found decreased ATP content and enhanced 
AMPK activity accompanied by increased autophagic activity, evidenced by enhanced 
autophagic protein levels and increased number of autophagic vacuoles, in hearts originated 
from Type I diabetic animals. Moreover, inhibition of autophagy further deteriorates normal 
cardiac functions of the animals, suggesting that autophagy protects Type I diabetic hearts. In 
the same study, decreased ATP content and AMPK activity were also observed. Despite 
enhanced levels of LC3-II and SQSTM1 in hearts from db/db animals, microscopic studies 
revealed reduced numbers of lysosomes and autolysosomes, indicating decreased autophagy.  
Induction of autophagy by resveratrol restored lysosomal and autophagic activity and 
improved cardiac functions. Conversly, Munasinghe et al, recently demonstrated increased 
expression of LC3-II and Beclin-1 and decreased p62 production, along with increased 
numbers of autophagosomes in samples taken from right atria of diabetic patients, in 
comparison with non-diabetic control donors [78]. The role of autophagy in diabetic heart 
appears mostly protective, but remains to be comprehensively characterized separately for 
Type I versus Type II diabetic conditions as the etiology of the two variants of diabetes is 
different:  e.g., lack of insulin in Type I and insulin resistance in Type II diabetes, as insulin 
itself regulates autophagy via mTOR [74,79]. 
Recent studies have demonstrated that autophagy may be induced at levels strongly protective 
against myocyte depletion and cardiac functional derangements associated with diabetic 
cardiomyopathy by heme oxygenase-1 (HO-1), a main component of cellular redox regulation 
and antioxidant defense [80]. Related investigations by Mahmoud et al., have further shown 
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that phytochemical induction of HO-1 derived from sour cherry seed suppresses disease-
associated inflammatory signaling in cells from patients with T2DM [81], rheumatoid 
arthritis, which is also a major co-morbidity of cardiovascular disease [82]. These 
investigators further demonstrated that a topically applied phytochemical inducer of HO-1 
derived from flavonoid sour cherry seed extract (SCSE), dramatically ameliorated the major 
symptoms of osteoarthritis (OA) in human patients, by targeted inhibition of inflammatory 
cytokine expression by CD3+ T cells [83]. This research initiative was the first successful 
demonstration of a “biotherapeutic” treatment of OA. Biotherapeutic methods attack root 
causes of disease (in this case, CD3+ T cell production of inflammatory cytokines), rather 
than simply treating symptoms. Conversely, most currently available “orthodox” treatments 
for OA and all other inflammatory syndromes, rely on palliative methods, typically small 
molecule drugs such as corticosteroids that are only temporarily effective and severely 
debilitating with sustained use. In the above example, the phytochemical HO-1 inducer 
utilized completely avoided adverse side effects. 
VIb – Autophagic influence on cell survival: clinical relevance. 
Ongoing studies of ischemic disease in cardiovascular tissue reveal that autophagic activity 
resulting in cell survival appears to be a significant factor in the amount of tissue that may 
survive for prolonged periods in chronically ischemic myocardium [84]. Moreover, this 
protective effect may be abolished with autophagy-inhibiting drugs such as wortmannin 
treatment, a pharmacological inhibitor of autophagy [85,86]. An autophagic process specific 
for clearance of defective mitochondria called “mitophagy” has also been shown to protect 
against ischemia-reperfusion (IR) injury [87,88]. These outcomes notwithstanding, 
precautions to prevent autophagic damage to the heart must be a major hallmark of clinical 
development of autophagy-based methodologies in cardiovascular medicine since under 
conditions of extreme tissue stress, high levels of autophagy may initiate cascades 
pathological reactions in myocardial cells and, ultimately, myocardial function derangement 
[14]. 
VIc - Evaluations of autophagy as a clinical correlate and possible contributor to atrial and 
ventricular fibrillation. 
Recently, authors of the present report evaluated the correlation between IR-induced VF and 
autophagy in heart tissue. In this investigation, it was observed that myocardial muscle of 
ischemia/reperfusion (I/R)-injured isolated fibrillated mouse hearts expressed significantly 
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higher level of Beclin-1, LC3B-II and the LC3B-II/LC3B-I ratio than non-fibrillated hearts 
[89]. These results establish a functional correlation between VF and autophagy; however, 
cause-effect relationships between the two phenomena remain to be defined. The present 
study and ongoing investigations, are designed to include components that will improve 
insight into the mechanistic relationships between VF and autophagy. Although correlation 
between VF and ischemia/reperfusion injury, has been extensively described, evidence 
linking autophagy to VF is limited at the time of this writing to the pioneering paper by 
authors of this report [89] and two others, in which the interaction of the two pathways is 
discussed indirectly [90,91]. The authors acknowledge that research in this topic area is not 
sufficiently mature at this point to comment extensively on it, and include mention of possible 
relationship between VF and autophagy to provide a perspective on promising research 
directions. 
Some insight provided by the authors, is provided in Figure 4, which illustrates the strikingly 
elevated levels of LC3B-II and the LC3B-II/LC3B-I ratio in muscle from hearts undergoing 
VF, versus non-VF hearts. Recently, Yuan and colleagues [88] have reported an enhanced 
level of p-AMPK in atrial tissue obtained from patient suffering from chronic atrial 
fibrillation (AF). Furthermore, the level of LC3BII was also enhanced in AF patient, 
indicating an AMPK-dependent autophagic activation. Similarly, time and AMPK dependent 
autophagy were found in canine model of AF [92]. In another study, enhanced autophagy was 
found in atria originated from patient suffering from mitral regurgitation in the presence or 
absence of AF [93]. However, in the aforementioned studies the functionality of autophagic 
process was not studied. Earlier, Garcia and colleagues have found enhanced number of 
autophagic vacuoles in atrial tissues from patient exhibiting postoperative atrial fibrillation 
[94]. However, in this study the level of LC3II was decreased compared to nonfibrillated 
atrial tissue, indicating an impaired autophagic process in the atrial tissue. The connection 
between ventricular arrhythmias and autophagy is further supported by a recent study 
conducted by Lu et al. [90]. After cardiac arrest induced by VF, resuscitated animals received 
epinephrine in the absence or presence of esmolol. Animal received epinephrine and esmolol 
simultaneously exhibited lower level of Beclin-1, and Parkin indicated that esmolol may 
reduce overactivation of autophagy and mitophagy [90]. Taken together the role of autophagy 
in myocardial arrhythmias is still unclear and further studies are required. 
VII. Autophagy-based cardiovascular therapies. 
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VIIa - Approaches for therapeutic utilization of autophagy: mechanistic considerations. 
Strategies for prevention and management of cardiovascular pathologies that modulate 
autophagic activity offer several major advantages over currently available therapies. One 
major benefit to patients of these approaches is that autophagy may often augmented using 
combinations of dietary phytochemicals [41], exercise [42]; and various other approaches that 
are non-toxic and non-invasive. Another significant advantage to development of autophagy-
based clinical methods is the potential for effective management of several very serious 
disorders that are refractory to currently available therapies. For example, although 
approximately 50% of the injury sustained by human hearts as a result of cardiac infarction, is 
due to I/R injury [95], there are no currently available preventive or therapeutic 
countermeasures to I/R-mediated tissue damage. Encouragingly however, recently, [96] 
reported that an inhibitor of histone deacetylase (HDAC), suberoylanilide hydroxamic acid 
(SAHA), increased cardiac autophagy in an animal model at sufficiently robust levels to 
reduce myocardial infarct size in I/R-injured hearts. 
VIIb - Clinical modulation of autophagy by calcineurn-inhibitory drugs. 
Another very exciting event in the exploration of autophagy as a cardiac therapy tool is a 
report by He et al., that suppression of cardiac autophagy with calcineurin, enhances oxidative 
damage to cardiomyocytes as a result of calcineurin-mediated inhibition of AMPK [97]. The 
aforementioned study additionally demonstrated that AMPK-mediated autophagy could be 
restored using FK506, an immunosuppressant drug widely used following organ transplant 
surgery to suppress allograft rejection. This development is of particular significance in the 
context of findings by Haines et al., demonstrating that FK506 effective dosage and thus 
toxicity could be drastically reduced by co-administration with a phytochemical mixture that 
reduced calcium influx to cells of the heart, thus enabling very low dosages of the drug to be 
used with high pharmacological effectiveness [1]. The capacity to use these and related 
strategies in ways that drastically reduce cardiotoxicity of drugs used to prevent or treat heart 
failure, opens up an expanding range of opportunities for improvements in cardiovascular 
medicine. A clinical venue, in which autophagy-related methods hold particular promise, is in 
the rapidly expanding field of stem cell therapy. Approaches to optimizing clinical benefits in 
this very exciting field are described below. 
VIIc – Strategies for therapeutic use of the unfolded protein response (UPR). The unfolded 
protein response (UPR), post-translational quality control countermeasure to the effects of 
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proteotoxic stress, described in section IVa of this article, offers expanded strategies for 
targeting molecular mechanisms leading to cellular senescence, along with a plethora of 
pathological outcomes, including arrhythmias. For example, studies of the effects of oxidative 
stress on mitogen-activated protein kinase (MAPK) signaling and UPR induction in a a 
neuronal-like catecholaminergic PC12 cell model, reveal that phosphorylation of eIF2 by 
PERK is observed to upregulate expression of heme oxygenase-1 (HO-1), through ATF4-
mediated activation of the Nrf2 pathway, which controls several genes critical for antioxidant 
defense, including HO-1 [98]. HO-1 expression is a major cellular countermeasure to 
oxidative stress.  Inducers of its activity are emerging as a therapeutic tool for prevention and 
management of a wide range of diseases [99] and it has recently been shown to counteract the 
effects of diabetic cardiomyopathy in mice through enhancement of autophagy in heart tissue 
[80]. This aforementioned dichotomy of cellular response to PERK activation underscores a 
fundamental flaw of the UPR with respect to its usefulness to an organism as an adaptive 
mechanism to ER stressors. Although it has evolved as a highly conserved adaptive reaction 
to toxic effects of caused by accumulation of misfolded proteins, activity of the UPR in 
response to protein aggregates may itself cause tissue damage in response to heavy burdens of 
such detritus, which typically occur as main features of several serious chronic neurologic 
disorders, notably, Parkinson’s disease, Huntington’s disease, the prion diseases and 
Alzheimer’s disease [48]. Constitutive UPR activation which develops to alleviate ER stress 
in these syndromes has pathological consequences that in the balance render activation of this 
pathway a significant contributor to their pathogenesis [48]. For instance, the severity of prion 
disease in mice was observed to strongly correlate with progressively increasing EIF2 
phosphorylation, with resultant suppression of translation and reduced availability of key 
synaptic proteins, neuronal cell death and debilitation of affected animals [100]. Significantly, 
oral treatment of mice with a PERK inhibitor which curtailed its phosphorylation of EIF2, 
allowed resumption of protein translation to levels sufficient to restore normal neurologic 
function and abrogate progression of the disease [100]. Future therapeutic use of PERK 
inhibitors may enhance the overall effectiveness of UPR-mediated alleviation of aggregate-
mediated cellular stress, however since selective inhibition of PERK nevertheless allows the 
IRE1- and ATF6-mediated arms of the UPR (shown in Figure 2) to retain functional activity, 
the benefits of curtailing EIF2phosphorylation are likely to outweigh the adverse effects. 
Ongoing drug discovery investigations will reveal to what extent this is true. 
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VIII. Autophagy and telocyte networks. 
For approximately 10 years prior to the date of this writing, emerging insight into the 
ultrastructure of cardiovascular tissue and mechanisms by which its component cells interact 
to maintain healthy homeostasis, have offered exciting promise for prevention and 
remediation of arrhythmic disorders, by enhancement of cardiac regenerative potential. A 
particularly strong contributor to these advances has been a rapidly evolving characterization 
of telocytes, a cell type first described in 2010 by a research group led by Professor Laurențiu 
M. Popescu. Subsequent exploration of telocyte biology revealed that these cells exert subtle 
but powerful effects on a wide range of tissues, including an intriguing capacity to stabilize 
the stem cell niche [101]. This last feature is particularly significant in the context of current 
efforts to restore healthy function of the heart and other organs by engraftment of progenitor 
stem cells derived from various tissues, including umbilical cord blood, adipose and 
hematopoietic tissue, embryonic stem cells; multipotent mesenchymal stromal cells and other 
sources. At the time of this writing, there is no evidence that telocytes are involved in 
ventricular fibrillation, moreover, their role in autophagy is in the preliminary stages of 
definition as described by the authors in Haines, et al, [18,101]. A comprehensive analysis of 
how these cells might affect VF awaits the outcome of ongoing investigations in-progress. 
This nothwithstanding, it was observed in rat model investigations, that tissue cardiac 
telocytes were depleted during myocardial infarction and improved resistance to and recovery 
from ischemic injury [102] and that intramyocardial transplantation of cardiac telocytes 
decreased myocardial infarction and improved post-infarcted cardiac function [103]. The 
significance of these findings to possible contribution of telocyte function to arrhythmias, is 
that treatments capable of inhibiting ischemia/reperfusion-mediated infarct zone extent (in rat 
heart), also improve cardiac function and delay post-ischemic onset of VF [104]. These 
indirect findings to not confirm telocyte involvement in arrhythmogenesis, but suggest that 
ongoing studies may reveal therapeutic targets involving telocyte function that allow 
improvement of VF and related cardiovascular syndromes, through modulation of autophagic 
processes and resulting amelioration of proteotoxic stress.  
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IX. Conclusions. 
As described in the foregoing sections, autophagy is a potent adaptive mechanism for 
maintaining healthy cellular homeostasis by clearing toxic cellular debris and allowing cells 
that might otherwise die to survive in functional forms that do not pose a hazard to 
surrounding tissue (as do senescent and carcinogenic forms). It is anticipated that 
understanding of autophagic processes will be particularly valuable in maintenance of cardiac 
health, with improvements in quality-of-life for elderly persons, being a major outcome. This 
prediction, is nevertheless made with the caveat that autophagy has the capacity to become 
pathological and development of therapies based on its induction must be undertaken with 
caution. A common feature of the various physiological processes to which autophagic 
activity is a contributor is that many stressors, in particular the toxic byproducts of oxidative 
metabolism accumulate in progressively larger numbers of cells over time, resulting in loss of 
functional tissue through cell death, cancers and emergence of senescent cellular phenotypes 
that damage tissue through expression of inflammatory mediators. Indeed the progressively 
pro-inflammatory tissue environment and decline of regenerative potential and tissue viability 
define physical aging on a very basic level [18]. Autophagy may this be viewed as a “braking 
system” which works against age- or trauma-associated physical decline, but is ultimately 
futile as individual tissues of an individual are depleted of functional quiescent cells and 
progenitor stem cells and are overwhelmed by the pro-inflammatory effect of damaged cells 
[18]. A fascinating implication of this phenomenon is explored by Herman Pontzer et al., 
[105]. These investigators demonstrated that within given time periods, the total energy 
expended by primates is much lower than placental mammals [105]. The significance of this 
observation in the context of tissue-deteriorating levels of proteotoxic stress is that autophagy 
in primates is likely to be more effective in holding off “wear-and-tear”-related (i.e., pro-
inflammatory) physical decline in primates than in shorter-lived animals. This hypothesis is 
currently speculative and unsupported by direct proof, but certainly defines a future direction 
in autophagy-related research. 
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Figures 
 
Figure 1. Progression of major macromolecular events in autophagic process. 
mTORC-mediated repression of autophagy is relieved by decreased nutrient availability and 
pro-autophagic downstream signaling thorough ULK1 and Beclin1–PI3KC3. The lipid 
mediator PI3P produced by Beclin1–PI3KC3 triggers WIP12/DFCP1-mediated assembly of 
the Atg Atg12–5–16 complex, in turn stimulating Atg8 (LC3)-induced progression of the 
degradation of targeted materials. 
 
Figure 2: Endoplasmic reticulum-associated degradation (ERAD) and unfolded protein 
responses (UPR). Nascent polypeptides emerging into the ER as they are translated from 
their associated ribosomes undergo folding through linkage of cysteine residues by protein 
disulfide isomerases (PDIs). N-terminal glycosylation forms binding sites for calnexin (CNX) 
and calreticulin (CRT). These chaperones along with Grp78 (BiP), direct malfoded proteins 
into retrotranslocation out of the ER, into degradation via the ubiquitin-proteasome pathway. 
ERAD constitutes a cell’s first line countermeasure to accumulation of potentially harmful 
metabolic detritus. Misfolded proteins displace GRP78/BiP from PERK, IRE1 and ATF6, 
thereby activating each factor. Activation of IRE1 mediates XBP1 splicing (sXBP1) and 
enhances lipids, chaperones ERAD proteins and also promotes autophagy. PERK activation 
globally reduces protein synthesis via eIF2a phosphorylation; and ATF6 is cleaved to nATF6, 
promoting expression of a variety of UPR target genes. 
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Figure 3. Regulation of and by the ULK1 complex during autophagy activation. Amino 
acid, glucose and serum starvation activate the ULK1 complex via separate signaling 
pathways. Autophosphorylation of ULK1 may maintain it in a conformation that is favorable 
for autophagy.  
Adapted from: Wirth M, Joachim J, Tooze S. Autophagosome formation—The role of ULK1 
and Beclin1–PI3KC3 complexes in setting the stage. Seminars in Cancer Biology 23  
(2013) 301– 309.  
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Figure 4. LC3B content in VF and non-VF post-IR heart tissue. A. Cardiac LC3B-I 
expression evaluated by Western immunoblotting and expressed relative to GAPDH content; 
B, Cardiac LC3B-I expression evaluated by Western immunoblotting and expressed relative 
to GAPDH content. Cardiac LC3B-II / LC3B-I ratio evaluated by Western immunoblotting 
(Data are presented as: n=4 per group, *p<0.05 No VF vs. VF hearts.) 
Adapted from: Meyer G, Czompa A, Reboul C, Csepanyi E, Czegledi A, Bak I, Balla G, Balla 
J, Tosaki A, Lekli I. The cellular autophagy markers Beclin-1 and LC3B-II are increased 
during reperfusion in fibrillated mouse hearts. Curr Pharm Des. 2013;19(39):6912-8. 
 
